Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Novo Nordisk has reported that the Japanese Ministry of Health, Labour and Welfare has approved Levemir, the company's long-acting modern insulin for use in type I and type II diabetes including combination treatment with oral antidiabetics.
Subscribe to our email newsletter
Novo Nordisk expects to launch Levemir (insulin detemir) in Japan in its prefilled FlexPen device and in Penfill for its NovoPen injection systems before the end of 2007. With the new approval, Novo Nordisk says it will be the only company in Japan offering rapid-acting, pre-mixed as well as long-acting modern insulins, allowing doctors and patients to tailor insulin regimens to each patient’s individual needs.
Kare Schultz, COO of Novo Nordisk, said: “Diabetes is a large and growing public health issue in Japan. With the launch of Levemir, we are providing an improved basal insulin, which we believe will benefit many patients.”